alastair gray
alastair gray
Emeritus Professor of Health Economics, University of Oxford
Adresse e-mail validée de
Citée par
Citée par
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
CT Trialists
The Lancet 376 (9753), 1670-1681, 2010
The economic burden of back pain in the UK
N Maniadakis, A Gray
Pain 84 (1), 95-103, 2000
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
B Mihaylova, J Emberson, L Blackwell, A Keech, J Simes, EH Barnes, ...
Lancet (London, England) 380 (9841), 581-590, 2012
Economic burden of cardiovascular diseases in the enlarged European Union
J Leal, R Luengo-Fernández, A Gray, S Petersen, M Rayner
European heart journal 27 (13), 1610-1619, 2006
Economic burden of cancer across the European Union: a population-based cost analysis
R Luengo-Fernandez, J Leal, A Gray, R Sullivan
The lancet oncology 14 (12), 1165-1174, 2013
European cardiovascular disease statistics 2012
M Nichols, N Townsend, R Luengo-Fernandez, J Leal, A Gray, ...
European Heart Network, 2012
European cardiovascular disease statistics
S Allender, P Scarborough, V Peto, M Rayner, J Leal, ...
European Heart Network 3, 11-35, 2008
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
PM Clarke, AM Gray, A Briggs, AJ Farmer, P Fenn, RJ Stevens, ...
Diabetologia 47 (10), 1747-1759, 2004
Applied methods of cost-effectiveness analysis in healthcare
AM Gray, PM Clarke, JL Wolstenholme, S Wordsworth
OUP Oxford, 2010
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
H Mehanna, M Robinson, A Hartley, A Kong, B Foran, T Fulton-Lieuw, ...
The Lancet 393 (10166), 51-60, 2019
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)
P Clarke, A Gray, R Holman
Medical Decision Making 22 (4), 340-349, 2002
European cardiovascular disease statistics
J Leal, R Luengo-Fernandez, A Gray
British Heart Foundation, 2000
Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)
A Gray, M Raikou, A McGuire, P Fenn, R Stevens, C Cull, I Stratton, ...
Bmj 320 (7246), 1373-1378, 2000
Handling uncertainty when performing economic evaluation of healthcare interventions.
AH Briggs, AM Gray
Health Technology Assessment (Winchester, England) 3 (2), 1-134, 1999
Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial
JN Primrose, R Perera, A Gray, P Rose, A Fuller, A Corkhill, S George, ...
Jama 311 (3), 263-270, 2014
Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART)
DP Taggart, DG Altman, AM Gray, B Lees, F Nugara, LM Yu, H Campbell, ...
European heart journal 31 (20), 2470-2481, 2010
A longitudinal study of the effects of age and time to death on hospital costs
M Seshamani, AM Gray
Journal of health economics 23 (2), 217-235, 2004
Measuring the impact of menopausal symptoms on quality of life.
E Daly, A Gray, D Barlow, K McPherson, M Roche, M Vessey
British medical journal 307 (6908), 836-840, 1993
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
UK Prospective Diabetes Study Group
Bmj 317 (7160), 720-726, 1998
Case management for people with severe mental disorders
M Marshall, A Gray, A Lockwood, R Green
Cochrane Database of Systematic Reviews, 1998
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20